Lille Cedex

• Safety of rotigotine in patients with autosomal dominant polycystic kidney disease - ETERNAL-PKD Recruiting
  2024-515734-32-00 4 2026-03-20 Kidney Disease
• DIAMOND Study - DIrect oral anticoagulant for Antithrombotic Management Of aortic bioprothesis implanted patients for valvular heart Disease … Recruiting
  2024-516643-64-00 5 2026-03-13 Aortic bioprothesis implanted patient for valvular heart disease
• Safety and efficacy of very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients undergoing percutaneou … Recruiting
  2023-507545-28-00 6 2026-03-06 Elderly patients ≥ 65 years successfully treated with percutaneous cor
• BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting
  2024-520128-27-00 4 2026-03-04 colorectal adenocarcinoma
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line … Recruiting
  2024-517766-41-00 4 2026-02-17 Patients with metastatic pancreatic ductal adenocarcinoma.
• A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting
  2024-516966-12-00 4 2026-02-13 Alzheimer’s disease
• Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection via Hysteroscopy in Severe Primary Dysmenorrhea: A Prospecti … Recruiting
  2025-520638-53-00 5 2026-02-09 Severe primary dysmenorrhea
• Randomised, controlled phase II proof-of-concept trial to assess the efficacy of abaCavIr/lamivudine treatment on the interferon signature i … Recruiting
  2023-508611-22-00 4 2026-02-03 systemic lupus
• A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious … Recruiting
  2023-508930-33-00 4 2026-01-30 Non-infectious active cryoglobulinemia vasculitis who are either refra
• Safety of Atezolizumab/Bevacizumab in liver transplanted patients with advanced hepatocellular carcinoma (IMMUNO-TH) Recruiting
  2024-514400-14-00 4 2026-01-23 liver transplanted patients with advanced hepatocellular carcinoma
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with S … Recruiting
  2024-520208-25-00 4 2026-01-15 Still’s disease
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• The purpose of this study is to determine whether Tislelizumab, when given as a subcutaneous (SC) injection, reaches the same drug levels in … Recruiting
  2025-522862-58-00 5 2026-01-09 Locally advanced unresectable or metastatic gastric or gastroesophagea
• ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RET … Recruiting
  2024-516244-25-00 5 2026-01-06 Kawasaki disease
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• A study of sepiapterin in participants with phenylketonuria (PKU) (EPIPHENY) Recruiting
  2024-514435-20-00 5 2025-12-23 Phenylketonuria
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou … Recruiting
  2025-521144-38-00 4 2025-12-23 Primary Central Nervous System Lymphoma
• OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro … Recruiting
  2022-501557-36-00 4 2025-12-19 PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
• Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study) Recruiting
  2024-518385-26-01 5 2025-12-18 Polymyalgia Rheumatica (PMR)

Showing 145–168 of 681 trials